API
< Back to all clusters
[HEALTH] · United States · 3 sources

started · updated

Oncology developments: New FDA approvals and radiation oncology service implementation

Recent advancements in oncology include new FDA approvals and strategic discussions regarding the implementation of radiation oncology service lines in community practices.

The FDA has granted accelerated approval to dostarlimab-gxly for adults with MSI-H/dMMR locally advanced rectal cancer (stage II or III). This immunotherapy approach may allow eligible patients to avoid chemotherapy, radiation, and surgery, though long-term relapse risks and surveillance requirements remain under study.

Additionally, tucatinib has seen expanded use in maintenance treatment for HER2-positive breast cancer. Other clinical updates include long-term survival findings for adjuvant ribociclib and warnings against extending immunotherapy intervals without sufficient data.

In the realm of practice management, Dr. Heath Skinner of the University of Pittsburgh Medical Center discussed the practicalities of launching new radiation oncology service lines. He noted that implementing low-dose radiation for osteoarthritis and benign conditions is the most accessible option for community practices, as it requires no new equipment and relies on building relationships with primary care and orthopedic colleagues.

Entities

FDA · Heath Skinner · Novartis · University of Pittsburgh Medical Center